CD19 and lymphoma: iPSC-derived iDuo NK cells were engineered with three components of CD19-CAR, non-cleavable CD16 (hnCD16) and a membrane-bound IL-15/IL-15R (IL-15RF) fusion protein to effectively eliminate both CD19 and CD20 lymphoma under anti-CD20 mAb and to extend their in vivo persistence [192].